

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

May 18, 2021

In the Matter of

Echo Therapeutics, Inc.

File No. 500-1

**ORDER OF SUSPENSION OF
TRADING**

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Echo Therapeutics, Inc. (“ECTE”)¹ (CIK No. 0001031927), a void Delaware corporation located in Iselin, New Jersey, with a class of securities registered with the Commission pursuant to the Securities Exchange Act of 1934 (“Exchange Act”) Section 12(g) because it is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 10-Q for the period ended September 30, 2016. On March 19, 2021, the Commission’s Division of Corporation Finance sent a delinquency letter to ECTE requesting compliance with its periodic filing requirements, but the delinquency letter was returned to sender due to ECTE’s failure to maintain a valid address on file with the Commission as required by Commission rules (Rule 301 of Regulation S-T, 17 C.F.R. Section 232.301 and Section 5.4 of EDGAR Filer Manual). As of April 26, 2021, the common stock of ECTE was quoted on OTC Link, had seven market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

¹ The short form of the issuer’s name is also its stock symbol.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of ECTE. Therefore, it is ordered, pursuant to Section 12(k) of the Exchange Act, that trading in the securities of the above-listed Company is suspended for the period from 9:30 a.m. EST on May 19, 2021, through 11:59 p.m. EST on June 2, 2021.

For the Commission, by the Division of Enforcement, pursuant to delegated authority.

Vanessa A. Countryman
Secretary